fig7

Systemic delivery of large-scale manufactured Wharton's Jelly mesenchymal stem cell-derived extracellular vesicles improves cardiac function after myocardial infarction

Figure 7. Hemodynamic PV loop measurements of cardiac function parameters. PV loop analysis of: (A) stroke work (SW); (B) cardiac output (CO); (C) stroke volume (SV); (D) ejection fraction (EF); (E) arterial elastance (Ea); (F) slope of end-systolic pressure-volume relationship (Ees); (G) volume-axis intercept of ESPVR (Vo); (H) preload recruitable stroke work (PRSW); and (I) slope of end-diastolic pressure-volume relationship (EDPVR). Placebo n = 13, WJMSC-EV-PLT n = 13, WJMSC-EV-FBS n = 10. *P < 0.05, **P < 0.01, ***P < 0.001. WJMSC: Wharton’s Jelly-derived mesenchymal stem cell; EV: extracellular vesicle; PLT: human platelet lysate; FBS: fetal bovine serum.

The Journal of Cardiovascular Aging

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/